However, only 10 different antigens are currently being targeted by mAbs developed for cancer therapies: EpCAM, MUC1, EGFR, CD20, CEA, HER2, CD22, CD33, Lewis Y and PSMA. This evidence concerns the gene CEACAM5 and cancer.